Somnomed Ltd
ASX:SOM

Watchlist Manager
Somnomed Ltd Logo
Somnomed Ltd
ASX:SOM
Watchlist
Price: 0.46 AUD -2.13% Market Closed
Market Cap: 99.4m AUD
Have any thoughts about
Somnomed Ltd?
Write Note

Somnomed Ltd
Cash & Cash Equivalents

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Somnomed Ltd
Cash & Cash Equivalents Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cash & Cash Equivalents CAGR 3Y CAGR 5Y CAGR 10Y
Somnomed Ltd
ASX:SOM
Cash & Cash Equivalents
AU$16.2m
CAGR 3-Years
-8%
CAGR 5-Years
16%
CAGR 10-Years
19%
ImpediMed Ltd
ASX:IPD
Cash & Cash Equivalents
AU$24.6m
CAGR 3-Years
8%
CAGR 5-Years
17%
CAGR 10-Years
9%
C
Cyclopharm Ltd
ASX:CYC
Cash & Cash Equivalents
AU$27.6m
CAGR 3-Years
-5%
CAGR 5-Years
37%
CAGR 10-Years
35%
Cochlear Ltd
ASX:COH
Cash & Cash Equivalents
AU$513.6m
CAGR 3-Years
-6%
CAGR 5-Years
46%
CAGR 10-Years
25%
Optiscan Imaging Ltd
ASX:OIL
Cash & Cash Equivalents
AU$6.1m
CAGR 3-Years
-10%
CAGR 5-Years
28%
CAGR 10-Years
56%
EMvision Medical Devices Ltd
ASX:EMV
Cash & Cash Equivalents
AU$18.6m
CAGR 3-Years
24%
CAGR 5-Years
34%
CAGR 10-Years
N/A
No Stocks Found

Somnomed Ltd
Glance View

Market Cap
99.4m AUD
Industry
Health Care

SomnoMed Ltd. produces and sells oral treatment of sleep related disorder devices. The company is headquartered in Sydney, New South Wales. The company went IPO on 2004-08-27. The firm provides treatment solutions for sleep-related breathing disorders, including obstructive sleep apnea, snoring, and bruxism. SomnoMed has developed the SomnoDent, a collection of oral devices. SomnoDent includes two product line, such as signature line and standard line. Its signature line products include Herbst Advance Elite, Fusion, Flex and Classic, and standard line products include Herbst Advance, Air/Air+, Morning Repositioner and Alpha. SomnoMed has developed the SomnoBrux, a custom fit acrylic occlusal splint. SomnoBrux product includes Michigan. SomnoMed has developed the SomGauge, is an autoclavable instrument, which can be used to construct accurate and reliable bite records.

SOM Intrinsic Value
0.78 AUD
Undervaluation 41%
Intrinsic Value
Price

See Also

What is Somnomed Ltd's Cash & Cash Equivalents?
Cash & Cash Equivalents
16.2m AUD

Based on the financial report for Jun 30, 2024, Somnomed Ltd's Cash & Cash Equivalents amounts to 16.2m AUD.

What is Somnomed Ltd's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
19%

Over the last year, the Cash & Cash Equivalents growth was 35%. The average annual Cash & Cash Equivalents growth rates for Somnomed Ltd have been -8% over the past three years , 16% over the past five years , and 19% over the past ten years .

Back to Top